Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Selective estrogen receptor modulator. Estrogen agonist in bone and estrogen receptor antagonist in breast and uterine tissue.
Indicated in treating osteoporosis and preventing breast cancer.
Raloxifene does not alter prolactin secretion in premenopausal women but increases levels of estradiol and sex-hormone binding globulin (BGSH).
At last update no published data on excretion in breast milk were found.
Pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of protein binding) make it unlikely milk passage of significant amounts.
Low oral bioavailability hinders the passage into infant plasma from ingested milk except in preterm neonates and immediate neonatal period, because an increased intestinal permeability can appear.
Although short-term treatments may be of low risk during breastfeeding, the anti-estrogenic effect on breast tissue, a prolonged use is not recommended.